PDCD1 and acute kidney injury: One large multicenter study investigated independent risk factors for ICPI-AKI demonstrating the greatest risk in patients receiving combination anti-CTLA-4 and anti-PD-1/PD-L1 agents (adjusted odds ratio, 3.88; 95% confidence interval, 2.21 to 6.81) (24).